A New Negotiation: Moving Payment for Medicines from Volume to Value
Across the health care system there is a movement to better pay for services based on outcomes. America's biopharmaceutical companies discussed ways the private prescription medicine marketplace can evolve to produce and reward better value for patients.
Speakers
- Stephen J. Ubl -- President & CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)
- Clifford A. Hudis, MD -- CEO, American Society of Clinical Oncology
- Tanisha Carino, Ph.D. -- Vice President, U.S. Public Policy, GlaxoSmithKline
- Samuel Nussbaum, MD -- Senior Fellow, USC Schaeffer Center for Health Policy and Economics; Former CMO, Anthem, Inc
- Marc M. Boutin, JD -- CEO, National Health Council
- Patricia J. Goldsmith -- CEO, CancerCare
When
Thursday, February 23, 2017
9:00 a.m. - 10:30 a.m.
Where
Morning Consult
729 15th St NW (1st floor)
Washington, DC 20005
Watch the event recap:
Sponsored by The Value Collaborative, an initiative of America's biopharmaceutical companies
About The Value Collaborative
Biopharmaceutical Innovation is advancing faster than ever before, and we need to make sure we have a payment and reimbursement system that is as innovative as the medicines. This is why the biopharmaceutical industry launched The Value Collaborative to bring researchers, caregivers, patients, payers and policymakers together to advance solutions that will enable the private sector to lead the move toward a value-driven health care system.
Event Photos
Stephen J. Ubl, president and CEO, PhRMA addresses audience on advancing value-driven health care
Michael Ramlet, CEO, Morning Consult; Marc Boutin, CEO, National Health Council; and Patricia Goldsmith, CEO, CancerCare discuss the importance of including the patient perspective in value assessments
In a fireside chat with Stephen Ubl, Dr. Clifford Hudis, CEO, American Society of Clinical Oncology, discusses approaches to promoting a health system that better rewards value
Michael Ramlet, CEO, Morning Consult; Tanisha Carino, vice president, GlaxoSmithKline and Dr. Samuel Nussbaum, senior fellow, USC Schaeffer Center talk about the successes, opportunities and challenges related to value-based payments
relatedResources
America’s Biopharmaceutical Companies Launch Groundbreaking, Multi-Year Initiative Heralding New Era of Medicine
PhRMA has launched a national, multi-year advertising and public affairs initiative on behalf of America’s biopharmaceutical companies. The campaign, GOBOLDLY, will showcase the industry’s unsung heroes driving cutting-edge advances in science and highlight the tremendous opportunity that exists to tackle our most complex and devastating health conditions.
The Value Collaborative
Recent advances in science are transforming our approach to treating and curing disease. As policymakers seek solutions to ensure patient access to the treatments they need and accelerate discovery of tomorrow’s cures, we need thoughtful reforms to advance payment and delivery systems that are as innovative as new medicines.